ncRNA basic information ncRNA ID: MIMAT0000263 ncRNA Database: miRBase ncRNA Name: miR-199b-5p ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-qPCR ncRNA Target Gene: WNT2 ncRNA Pathway: WNT2-mediated Beta-catenin signaling pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00619 (APRD01028, EXPT02967, DB03261) Drug Name: Imatinib Drug Method: Higher protective autophagy was identified in IM-resistant K562 (K562R) cells. Inhibition of autophagy by the inhibitors, chloroquine and 3-methyladenine, enhanced IMs efficacy in K562R cells. In addition, microRNA (miR)-199a/b-5p were downregulated in K562R cells compared to parent cells. Overexpression of miR-199a/b-5p reduced autophagy and induced cell apoptosis, resulting in enhanced IMs efficacy in K562R cells. Moreover, expression levels of the Wingless-type MMTV integration site family member 2 (WNT2), a positive regulator of autophagy, were significantly higher in K562R cells, and it was validated as a direct target gene of miR-199a/b-5p. Overexpressions of miR-199a/b-5p inhibited WNT2 downstream signaling. Furthermore, overexpression and knockdown of WNT2 influenced autophagy formation and CML drug sensitivity to IM. Overexpression of WNT2 could also reverse miR-199a/b-5p-enhanced IM efficacy in K562R cells. These results emphasized that miR-199a/b-5p inhibited autophagy via repressing WNT2 signaling and might provide novel therapeutic strategies for future IM-resistant CML therapy and drug development. Drug Response: sensitive

Cancer basic information Cancer: chronic myeloid leukemia Tissue/Cell: cell line (K562, K562R, KU812, and KU812R)

Other information Title: microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. Journal: Chem Biol Interact Published: 2018 PubMed ID: 29890129